HK1121762A1 - Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders - Google Patents

Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders

Info

Publication number
HK1121762A1
HK1121762A1 HK09101838.5A HK09101838A HK1121762A1 HK 1121762 A1 HK1121762 A1 HK 1121762A1 HK 09101838 A HK09101838 A HK 09101838A HK 1121762 A1 HK1121762 A1 HK 1121762A1
Authority
HK
Hong Kong
Prior art keywords
intermediates
gastrointestinal
treatment
nervous system
central nervous
Prior art date
Application number
HK09101838.5A
Other languages
English (en)
Inventor
Kolbot By
J B Yeh
Ponny Pang
Original Assignee
Armetheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armetheon Inc filed Critical Armetheon Inc
Publication of HK1121762A1 publication Critical patent/HK1121762A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
HK09101838.5A 2005-08-31 2009-02-26 Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders HK1121762A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71314905P 2005-08-31 2005-08-31
US74776206P 2006-05-19 2006-05-19
PCT/US2006/034322 WO2007028073A2 (en) 2005-08-31 2006-08-31 Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders

Publications (1)

Publication Number Publication Date
HK1121762A1 true HK1121762A1 (en) 2009-04-30

Family

ID=37708472

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09101838.5A HK1121762A1 (en) 2005-08-31 2009-02-26 Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders

Country Status (15)

Country Link
US (3) US7326787B2 (xx)
EP (1) EP1919909B1 (xx)
JP (1) JP5308818B2 (xx)
KR (1) KR101351454B1 (xx)
CN (1) CN102863374A (xx)
AU (1) AU2006284601B2 (xx)
BR (1) BRPI0615691A8 (xx)
CA (1) CA2620379C (xx)
DK (1) DK1919909T3 (xx)
ES (1) ES2436100T3 (xx)
HK (1) HK1121762A1 (xx)
IL (1) IL189202A (xx)
NO (1) NO340832B1 (xx)
RU (1) RU2418798C2 (xx)
WO (1) WO2007028073A2 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
RU2418798C2 (ru) * 2005-08-31 2011-05-20 Арикс Терапьютикс, Инк. Способы синтеза и промежуточные соединения при синтезе стереоизомерных соединений, пригодных для лечения желудочно-кишечных расстройств и расстройств центральной нервной системы
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
IT1396373B1 (it) * 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US9956393B2 (en) 2015-02-24 2018-05-01 Elira, Inc. Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
US20220062621A1 (en) 2015-02-24 2022-03-03 Elira, Inc. Electrical Stimulation-Based Weight Management System
EP3261712B1 (en) 2015-02-24 2024-04-03 Elira, Inc. System for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
US10335302B2 (en) 2015-02-24 2019-07-02 Elira, Inc. Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
TW202024081A (zh) * 2018-11-05 2020-07-01 美商瑞內克松有限公司 生產三水合那羅普來得(naronapride)之方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB1425706A (en) 1972-06-30 1976-02-18 Wyeth John & Brother Ltd Piperidine derivatives
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4870074A (en) 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
US4875439A (en) * 1987-01-09 1989-10-24 Brunswick Corporation Marine propulsion system with fuel line cooler
US4975439A (en) 1987-09-25 1990-12-04 Janssen Pharmaceutical N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
CA1317940C (en) 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5041454A (en) 1987-09-25 1991-08-20 Janssen Pharmaceutica N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
GB8902118D0 (en) * 1989-02-01 1989-03-22 Beecham Group Plc Chemical process
TW213460B (xx) 1991-02-15 1993-09-21 Hokuriku Pharmaceutical
US5395832A (en) 1991-02-15 1995-03-07 Hokuriku Seiyaku Co., Ltd. Benzamide derivatives
EP0612313A1 (en) * 1991-11-14 1994-08-31 Glaxo Group Limited Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
IT1260485B (it) 1992-05-29 1996-04-09 Procedimento e dispositivo per il trattamento dell'obesita' di un paziente
CA2139636A1 (en) 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
CA2139638A1 (en) 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
NZ257545A (en) 1992-11-05 1997-01-29 Smithkline Beecham Plc Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions
US5472866A (en) 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
US5712293A (en) 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
PL190296B1 (pl) 1997-07-11 2005-11-30 Janssen Pharmaceutica Nv Zastosowanie (+)-norcyzaprydu
JPH11292846A (ja) 1998-02-10 1999-10-26 Hokuriku Seiyaku Co Ltd ベンズアミド誘導体及びそれを含有する医薬
AR022338A1 (es) 1999-02-04 2002-09-04 Hokuriku Pharmaceutical Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal.
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US20040092511A1 (en) 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
AU2001275326C1 (en) 2000-06-07 2006-09-21 Aryx Therapeutics Treatment of gastroesophageal reflux disease using piperidine derivatives
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
ATE464308T1 (de) * 2004-01-07 2010-04-15 Aryx Therapeutics Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems
RU2418798C2 (ru) 2005-08-31 2011-05-20 Арикс Терапьютикс, Инк. Способы синтеза и промежуточные соединения при синтезе стереоизомерных соединений, пригодных для лечения желудочно-кишечных расстройств и расстройств центральной нервной системы

Also Published As

Publication number Publication date
KR101351454B1 (ko) 2014-01-14
EP1919909A2 (en) 2008-05-14
JP5308818B2 (ja) 2013-10-09
RU2008112215A (ru) 2009-10-10
JP2009507033A (ja) 2009-02-19
CN102863374A (zh) 2013-01-09
NO20081562L (no) 2008-03-28
US20080076927A1 (en) 2008-03-27
IL189202A0 (en) 2008-06-05
DK1919909T3 (da) 2013-12-02
ES2436100T3 (es) 2013-12-27
CA2620379A1 (en) 2007-03-08
CA2620379C (en) 2015-02-24
US20090137810A1 (en) 2009-05-28
NO340832B1 (no) 2017-06-26
EP1919909B1 (en) 2013-08-21
WO2007028073A3 (en) 2007-05-24
US7326787B2 (en) 2008-02-05
WO2007028073A2 (en) 2007-03-08
BRPI0615691A8 (pt) 2017-08-15
AU2006284601A1 (en) 2007-03-08
BRPI0615691A2 (pt) 2011-05-24
KR20080041294A (ko) 2008-05-09
IL189202A (en) 2013-07-31
RU2418798C2 (ru) 2011-05-20
US7629466B2 (en) 2009-12-08
US20070078265A1 (en) 2007-04-05
AU2006284601B2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
HK1121762A1 (en) Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
HUS1900005I1 (hu) Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére
IL178648A0 (en) Substituted morpholine compounds for the treatment of central nervous system disorders
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
IL185016A0 (en) Compounds for the treatment of proliferative disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
PL1890684T3 (pl) Leczenie zaburzeń snu i czuwania
IL176581A0 (en) Immunomodulatory compounds for the treatment of central nervous system disorders
EP1853539A4 (en) HONOKIOL DERIVATIVES TO TREAT PROLIFERATIVE DISEASES
IL190920A0 (en) Compounds for the treatment of metabolic disorders
HK1157575A1 (en) Treating neurological disorders
EP2268140A4 (en) NOVEL COMPOUNDS FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM
ZA200801667B (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
SI2418201T1 (sl) Polimorfne oblike (2s)-(4e)-n-metil-5(3-(5-izopropksipiridin)-il)-4-pen-ten-2-amin p-hidroksibenzoata za zdravljenje motenj osrednjega ĺ˝iväśnega sistema
IL187248A0 (en) Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
PL1841433T3 (pl) Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego
EP1901770A4 (en) METHOD FOR TREATING GROWTH TROUBLESHOOTING
ZA200805108B (en) Treatment of neurodegenerative disorders
ZA200802270B (en) Treatment of neurodegenerative disorders
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
ZA200801144B (en) Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
GB0604772D0 (en) Use of substituted amine compounds for the treatment of food related disorders
GB0507552D0 (en) Methods and compounds for the treatment of cognitive dysfunction
GB0512757D0 (en) Treatment of respiratory disorders
GB0410966D0 (en) Treatment of neural disorders